Microdosing GLP-1

"Microdosing" GLP-1 medications is a community-driven practice — not an FDA-approved or studied regimen — where patients use smaller doses than the lowest FDA-approved starting dose. For semaglutide, the approved starting dose is 0.25 mg per week; microdosing reports range from 0.05 mg to 0.2 mg per week. For tirzepatide, the approved start is 2.5 mg per week; microdosing reports range from 0.5 mg to 2 mg per week.

There are no randomized clinical trials of microdosing. The published efficacy and safety data on GLP-1s exists only for the labeled dose ranges. Everything below the starting dose is, by definition, off-label and unproven. This guide explains what people are actually doing, the theoretical rationale they cite, and the honest gaps in what's known.

This is not a recommendation. The practice is genuinely off-label and the risks — particularly dosing errors with compounded vials — are real and documented.

What it actually means

The standard FDA-approved titration for semaglutide (Wegovy or Ozempic) starts at 0.25 mg once weekly and escalates every four weeks: 0.5 mg, 1 mg, 1.7 mg, 2.4 mg (or 2 mg for Ozempic). The standard titration for tirzepatide (Zepbound or Mounjaro) starts at 2.5 mg weekly and escalates: 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg.

Microdosing departs from this schedule on the low end. Patients describe several patterns:

• Sub-starting doses indefinitely — staying at 0.1 mg or 0.2 mg semaglutide per week, never advancing.
• Slow micro-titration — increasing by 0.05 mg or 0.1 mg semaglutide rather than the standard 0.25 mg jumps.
• Maintenance microdosing — after losing weight on standard doses, dropping to a much lower dose for long-term maintenance.

In practice, microdosing has been almost exclusively done with compounded multi-dose vials, because pre-filled brand-name pens only deliver the FDA-approved doses. With the legal cover for compounded GLP-1s largely ending in 2024–2025, the population of microdosers has shifted — some moved onto LillyDirect or NovoCare vials (which can technically be drawn at smaller volumes, though that's also off-label use of the FDA-approved product), and some left the practice entirely.

What the evidence actually shows

There is no peer-reviewed clinical trial of microdosed GLP-1s for weight loss, diabetes, or any other condition. Manufacturer Phase II and Phase III trials tested only the labeled dose ranges. The published pharmacology data does suggest that GLP-1 receptor activity is dose-dependent: lower doses produce smaller effects on gastric emptying, satiety, and glucose. Whether very low doses produce any meaningful clinical effect is unknown.

The community rationale for microdosing usually rests on three claims:

Reduced side effects. GLP-1 nausea, vomiting, and constipation are dose-dependent — they are more common at higher doses and during titration. Patients who are very sensitive may experience meaningful gastrointestinal symptoms at the 0.25 mg starting dose and reason that a smaller dose would cause fewer. This is biologically plausible but unproven in a controlled study.

Cost extension. A vial of compounded or brand semaglutide lasts longer if you use less per dose. This is a real economic argument, but it conflates a financial benefit with a clinical one.

Maintenance after weight loss. Once goal weight is reached, the manufacturer-recommended approach for long-term use is continuing the maintenance dose (e.g., 2.4 mg semaglutide for Wegovy). Some patients and clinicians have explored stepping down to lower doses for maintenance. There is limited and growing observational data on this — most notably from clinical practice rather than from randomized trials — but no formal labeling for lower maintenance doses.

None of these claims are unreasonable hypotheses. They are also not validated treatments.

The real risks

Common questions

Keep exploring

Browse all dosing guides.